Back to top
more

Clover Health Investments (CLOV)

(Delayed Data from NSDQ)

$2.78 USD

2.78
7,403,773

-0.11 (-3.81%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $2.81 +0.03 (1.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks Industry Outlook Highlights Definitive Healthcare, Clover Health and Augmedix

by Zacks Equity Research

Healthcare, Clover Health and Augmedix are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Consider From a Prospering Industry

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Definitive Healthcare (DH), Clover Health Investments (CLOV) and Augmedix (AUGX) are expected to gain from new normal trends.

Zacks Equity Research

Fast-paced Momentum Stock Clover Health Investments, Corp. (CLOV) Is Still Trading at a Bargain

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Clover Health Investments, Corp. (CLOV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Andrew Rocco headshot

Bear of the Day: Icahn Enterprises (IEP)

by Andrew Rocco

IEP stock is getting crushed this year as an inflated NAV, poor fundamentals, and negative headlines present obstacles.

Zacks Equity Research

Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Ligand Pharmaceuticals (LGND) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Equity Research

Is Clover Health Investments (CLOV) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Clover Health Investments, Corp. (CLOV) and Pyxis Oncology, Inc. (PYXS) have performed compared to their sector so far this year.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 21.05% and 7.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks Equity Research

Down 22.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Clover Health Investments, Corp. (CLOV)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Clover Health Investments, Corp. (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 48.39% and 3.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of 17.78% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 4.35% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Signify Health (SGFY) Q2 Earnings Beat Estimates

by Zacks Equity Research

Signify (SGFY) delivered earnings and revenue surprises of 130% and 1.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 20.83% and 7.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health (CLOV) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.

Zacks Equity Research

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Omnicell (OMCL) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 16.90% and 0.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

UnitedHealth (UNH) to Post Q1 Earnings: What to Expect

by Zacks Equity Research

UnitedHealth Group's (UNH) first-quarter results are likely to reflect the benefits of improving premiums and products.

Zacks Equity Research

Universal Health (UHS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Universal Health Services' (UHS) fourth-quarter results are likely to reflect the benefits of improving patient volumes.

Zacks Equity Research

Mednax (MD) to Post Q4 Earnings: Here's What You Need to Know

by Zacks Equity Research

Mednax's (MD) fourth-quarter results are likely to reflect growth in same-unit revenues and NICU days.

Zacks Equity Research

Will Patient Days Drive Community Health (CYH) Q4 Earnings?

by Zacks Equity Research

Community Health Systems' (CYH) fourth-quarter results are likely to reflect a higher occupancy rate and average length of stay.

Daniel Laboe headshot

Bullish SoFi (SOFI) Option Spread For Upside Catalysts Ahead

by Daniel Laboe

I'm looking at a bullish SOFI spread that will maximize upside potential and minimize upfront costs

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Clover Health Investments, Corp. (CLOV) closed at $4.09, marking a -0.24% move from the previous day.

Zacks Equity Research

Is the Options Market Predicting a Spike in Clover Health (CLOV) Stock?

by Zacks Equity Research

Investors need to pay close attention to Clover Health (CLOV) stock based on the movements in the options market lately.